WO2005054426A3 - Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof - Google Patents
Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof Download PDFInfo
- Publication number
- WO2005054426A3 WO2005054426A3 PCT/SE2004/001814 SE2004001814W WO2005054426A3 WO 2005054426 A3 WO2005054426 A3 WO 2005054426A3 SE 2004001814 W SE2004001814 W SE 2004001814W WO 2005054426 A3 WO2005054426 A3 WO 2005054426A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- angiogenesis
- compositions
- proteins
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/40—Fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002548208A CA2548208A1 (en) | 2003-12-05 | 2004-12-06 | Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof |
JP2006542541A JP2007512835A (en) | 2003-12-05 | 2004-12-06 | Polypeptides, proteins and compositions affecting angiogenesis and methods of using the same |
AU2004295654A AU2004295654A1 (en) | 2003-12-05 | 2004-12-06 | Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof |
NZ547877A NZ547877A (en) | 2003-12-05 | 2004-12-06 | Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof |
EP04801722A EP1699818A2 (en) | 2003-12-05 | 2004-12-06 | Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use |
US10/581,761 US20090036362A1 (en) | 2003-12-05 | 2004-12-06 | Angiogenesis Affecting Polypeptides, Proteins, and Composition, and Methods of Use Thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48174103P | 2003-12-05 | 2003-12-05 | |
US60/481,741 | 2003-12-05 | ||
SE0303268A SE0303268D0 (en) | 2003-12-05 | 2003-12-05 | Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof |
SE0303268-7 | 2003-12-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005054426A2 WO2005054426A2 (en) | 2005-06-16 |
WO2005054426A3 true WO2005054426A3 (en) | 2005-08-04 |
Family
ID=34656372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2004/001814 WO2005054426A2 (en) | 2003-12-05 | 2004-12-06 | Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1699818A2 (en) |
JP (1) | JP2007512835A (en) |
AU (1) | AU2004295654A1 (en) |
CA (1) | CA2548208A1 (en) |
NZ (2) | NZ577564A (en) |
WO (1) | WO2005054426A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2042514A1 (en) * | 2007-09-25 | 2009-04-01 | Life & Brain GmbH | Maintenance of hair growth and treatment of hair-loss |
LT3485903T (en) | 2011-09-23 | 2023-02-27 | Mereo Biopharma 5, Inc. | Vegf/dll4 binding agents and uses thereof |
EP3353204B1 (en) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1114862A2 (en) * | 1999-11-17 | 2001-07-11 | Switch Biotech Aktiengesellschaft | Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in indentifying pharmacologically acitve substances |
WO2003026403A2 (en) * | 2001-09-24 | 2003-04-03 | Deltagen, Inc. | Ctsz disruptions, compositions and methods relating thereto |
US20030100497A1 (en) * | 2001-06-20 | 2003-05-29 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
WO2003046578A2 (en) * | 2001-11-29 | 2003-06-05 | Novartis Ag | Method for the assessment and prognosis of sarcoidosis |
WO2003072827A1 (en) * | 2001-10-31 | 2003-09-04 | Children's Hospital Medical Center | Method for diagnosis and treatment of rheumatoid arthritis |
EP1347059A1 (en) * | 2002-03-20 | 2003-09-24 | Biofrontera Pharmaceuticals AG | Cathepsin Y for the development of a medicament for the treatment of stroke |
WO2003079982A2 (en) * | 2002-03-19 | 2003-10-02 | Tularik Inc. | Gene amplification in cancer |
WO2004030615A2 (en) * | 2002-10-02 | 2004-04-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
-
2004
- 2004-12-06 NZ NZ577564A patent/NZ577564A/en unknown
- 2004-12-06 NZ NZ547877A patent/NZ547877A/en unknown
- 2004-12-06 AU AU2004295654A patent/AU2004295654A1/en not_active Abandoned
- 2004-12-06 EP EP04801722A patent/EP1699818A2/en not_active Withdrawn
- 2004-12-06 WO PCT/SE2004/001814 patent/WO2005054426A2/en active Application Filing
- 2004-12-06 JP JP2006542541A patent/JP2007512835A/en not_active Abandoned
- 2004-12-06 CA CA002548208A patent/CA2548208A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1114862A2 (en) * | 1999-11-17 | 2001-07-11 | Switch Biotech Aktiengesellschaft | Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in indentifying pharmacologically acitve substances |
US20030100497A1 (en) * | 2001-06-20 | 2003-05-29 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
WO2003026403A2 (en) * | 2001-09-24 | 2003-04-03 | Deltagen, Inc. | Ctsz disruptions, compositions and methods relating thereto |
WO2003072827A1 (en) * | 2001-10-31 | 2003-09-04 | Children's Hospital Medical Center | Method for diagnosis and treatment of rheumatoid arthritis |
WO2003046578A2 (en) * | 2001-11-29 | 2003-06-05 | Novartis Ag | Method for the assessment and prognosis of sarcoidosis |
WO2003079982A2 (en) * | 2002-03-19 | 2003-10-02 | Tularik Inc. | Gene amplification in cancer |
EP1347059A1 (en) * | 2002-03-20 | 2003-09-24 | Biofrontera Pharmaceuticals AG | Cathepsin Y for the development of a medicament for the treatment of stroke |
WO2004030615A2 (en) * | 2002-10-02 | 2004-04-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
Non-Patent Citations (7)
Title |
---|
BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1491, 2000, pages 93 - 106 * |
BOHLING F. ET AL.: "Cathepsins K, L, B, X and W are differentially expressed in normal and chronically inflamed gastric mucosa", BIOL. CHEM., vol. 385, May 2004 (2004-05-01), pages 439 - 445 * |
DATABASE EMBL [online] DEUSSING J. ET AL.: "Murine and human cathepsin Z: cDNA-cloning, characterization of the genes and chromosomal localization", Database accession no. (AF136273) * |
DATABASE EPOP [online] Database accession no. (AX140435) * |
DATABASE GENESEQ [online] Database accession no. (ABM82268) * |
DATABASE GENESEQ [online] Database accession no. (ADD49940) * |
DATABASE GENESEQ [online] Database accession no. (ADP65017) * |
Also Published As
Publication number | Publication date |
---|---|
NZ547877A (en) | 2009-07-31 |
WO2005054426A2 (en) | 2005-06-16 |
NZ577564A (en) | 2010-04-30 |
JP2007512835A (en) | 2007-05-24 |
EP1699818A2 (en) | 2006-09-13 |
AU2004295654A1 (en) | 2005-06-16 |
CA2548208A1 (en) | 2005-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004076639A3 (en) | Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus | |
ATE269402T1 (en) | IKK-BETA PROTEINS, NUCLEIC ACIDS AND METHODS | |
WO1999058675A3 (en) | Human genes and gene expression products v | |
WO2002014500A3 (en) | Human genes and gene expression products | |
WO1999038972A9 (en) | Human genes and gene expression products ii | |
DK1641818T3 (en) | Polypeptides that have binding affinity for HER2 | |
WO2001066753A3 (en) | Human genes and gene expression products | |
WO2008136848A3 (en) | Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease | |
WO2002088750A3 (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
MXPA02008239A (en) | Human schizophrenia gene. | |
WO2001071357A3 (en) | Diagnosis and treatment of breast cancer | |
DE69826493D1 (en) | IKK-ALPHA PROTEINS, NUCLEIC ACIDS AND METHOD | |
WO2005026205A3 (en) | Genetic products which are differentially expressed in tumours and use thereof | |
WO2004094476A3 (en) | Compositions and methods relating to stop-1 | |
WO1999051186A3 (en) | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders | |
WO2004066933A3 (en) | Compositions and methods for treating cancer using igsf9 and liv-1 | |
EP1197550A3 (en) | Methods and compositions for diagnosing and treating disorders involving angiogenesis | |
WO2005054426A3 (en) | Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof | |
WO2001020026A3 (en) | POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | |
WO2003076658A3 (en) | A susceptibility gene for late-onset idiopathic parkinson's disease | |
MXPA03010728A (en) | B7 related protein-2 molecules and uses thereof. | |
WO2001064876A3 (en) | Human schizophrenia gene | |
SE0303268D0 (en) | Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof | |
WO2000018916A3 (en) | Human genes and gene expression products | |
WO2001072781A3 (en) | Human genes and expression products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2548208 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006542541 Country of ref document: JP Ref document number: 2004295654 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004801722 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 547877 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3720/DELNP/2006 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2004295654 Country of ref document: AU Date of ref document: 20041206 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004295654 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200480040284.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2004801722 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10581761 Country of ref document: US |